Home Tags Sanofi

Tag: Sanofi

Also Noted

Sanofi seeks expanded reach for diabetes drug  

January 5, 2026HME News Staff

PARIS – Sanofi has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental biologic license application (sBLA) for Tzield (teplizumab-mzwv) to expand the current age indication from eight years and above to as young as one year old and above to delay the onset of stage 3 Type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. The company says the sBLA is supported by the positive interim one-year data...

Diabetes, Food & Drug Administration (FDA), Sanofi

Read Full Articlered right arrow icon